This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

András Perényi, MD; Mihály Arató, MD
National Institute for Nervous and Mental Diseases 1281 Budapest 27 Pf 1, Hungary

Arch Gen Psychiatry. 1984;41(7):727.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

In connection with the study of Kane et al,¹ we would like to refer to our previous study, which was presented at the Third World Congress on Biological Psychiatry² and was only published in Hungarian.³ In a double-blind study, Kane et al compared a low-dosage regimen of fluphenazine decanoate (1.25 to 5.0 mg every two weeks) with the standard-dosage regimen (12.5 to 50 mg every two weeks) and reported on the relapse rate and abnormal involuntary movements. The relapse rate was considerably higher in the low-dose group, but their results were encouraging with regard to the movement disorders.

In our study,^2,3 we carried out a tardive dyskinesia (TD) prevalence study on 88 outpatient schizophrenics receiving depot neuroleptics (fluphenazine decanoate, flupentixol decanoate, and fluspirilene). The patients were in good mental condition and had not had any relapse for at least three months, with most . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?